To present longitudinal changes in Functional Assessment of Cancer Therapy-Prostate ( FACT-P ) scores during @-week treatment with enzalutamide or placebo in men with progressive metastatic castration-resistant prostate cancer ( mCRPC ) after chemotherapy in the AFFIRM trial .